Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Lilly's Retatrutide Delivered Significant Weight Loss, A1C Reduction In Phase 3 Trial

(RTTNews) - Eli Lilly and Company (LLY) reported detailed Phase 3 TRIUMPH-2 results showing that Retatrutide delivered substantial weight loss and blood sugar reductions in adults with obesity or overweight and type 2 diabetes.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

Morning Bid: A cruel quarter for bonds

  • US 10-year Treasury yield rises 81 basis points in July-September
  • Japan's 10-year bond yield increases 42 basis points, biggest rise in 2 decades
  • Economic data releases expected to clarify European economy and monetary policy outlook

More from Wednesday 30 September →